Eyenovia, Inc. — 2023 Form 10-K Summary
Issuer check: The supplied filing is for Eyenovia, Inc. (Nasdaq: EYEN), not Hyperion DeFi, Inc. The filing covers the fiscal year ended December 31, 2023 and was signed March 18, 2024.
Business context and reporting period
Eyenovia is an ophthalmic technology company developing and commercializing drug-device products using its Optejet microdose delivery system. Its product and pipeline focus includes Mydcombi for pupil dilation, clobetasol propionate for post-operative ocular inflammation and pain, MicroLine for presbyopia, and MicroPine for pediatric progressive myopia. Mydcombi began a targeted commercial launch in August 2023. Clobetasol propionate was approved by the FDA on March 4, 2024, after the fiscal year-end.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $3,787 | $0 |
| Cost of revenue / gross profit | $3,787 / $0 | $0 / $0 |
| Research and development expense | $13.0 million | $13.4 million |
| General and administrative expense | $12.4 million | $13.5 million |
| Operating loss | $25.4 million | $26.9 million |
| Net loss | $27.3 million | $28.0 million |
| Basic and diluted loss per share | $0.66 | $0.83 |
| Cash used in operating activities | $23.8 million | $25.1 million |
At December 31, 2023, cash and cash equivalents were $14.8 million, down from $22.9 million a year earlier; working capital was $11.2 million, versus $23.1 million. Net cash used in investing activities was $4.0 million, including $2.9 million for property and equipment and $1.1 million for the Formosa license. Financing activities provided $19.8 million, primarily from equity offerings and Avenue borrowing.
Gross notes payable were $15.6 million, including a $637,500 final payment; the balance-sheet carrying amount was approximately $14.3 million after debt discounts. The Avenue facility is secured by substantially all company assets, including intellectual property, and matures November 1, 2025. Total assets were $28.8 million and total liabilities $19.8 million. The company reported an accumulated deficit of $145.5 million.
Material changes versus 2022
- Revenue began with Mydcombi’s first commercial sale in August 2023, but was immaterial and fully offset by product cost, leaving no gross profit.
- Net loss narrowed by about $0.8 million; operating expenses declined by about $1.5 million. Higher interest expense partly offset these reductions.
- Operating cash use improved by about $1.3 million, while year-end cash fell by $8.0 million.
- The company raised an additional $5.0 million under its Avenue facility in May 2023 and raised equity through registered direct and at-the-market offerings. Common shares outstanding increased from 36.7 million at year-end 2022 to 45.6 million at year-end 2023.
- In August 2023, Eyenovia licensed U.S. commercial rights to clobetasol propionate from Formosa for $2.0 million upfront, consisting of $1.0 million cash and $1.0 million in shares, plus up to $4 million in development milestones and $80 million in sales milestones.
Outlook, commentary, risks and unusual items
- Going concern: Management and the auditor concluded that substantial doubt exists about Eyenovia’s ability to continue as a going concern for at least one year after issuance of the financial statements. The company has no recurring revenue, expects continuing operating cash outflows, and says it needs additional capital or sufficient revenue; management cannot assure that financing will be available. Failure to secure funds could require cuts to development or operations.
- Commercial plans: Management planned to expand the Mydcombi launch during 2024 with a ten-person sales team and internal manufacturing capacity. It anticipated launching clobetasol propionate in the second half of 2024. These are forward-looking plans, not reported outcomes.
- Pipeline: Eyenovia planned an FDA meeting in mid-2024 on transitioning MicroLine to its lower-cost Gen-2 Optejet and anticipated discussing a MicroPine interim analysis in late 2024. It projected that Gen-2 could reach the commercial market in 2026, subject to FDA agreement on comparability.
- MicroPine rights: In January 2024, Eyenovia agreed to reacquire U.S. and Canadian rights from Bausch + Lomb, pay $2 million cash and $3 million in shares upon transfer of regulatory and study materials, and pay a 2% royalty on future U.S. net sales, subject to approval.
- Debt and dilution: Avenue debt carries a variable interest rate, asset liens, covenants and default provisions. Further capital raising may dilute shareholders or constrain operations. At March 15, 2024, the company disclosed 47.4 million common shares outstanding, plus warrants, options, convertible debt and other potential share issuances.
- Clinical supply issue: A clinical-supply return/rework estimate was initially accrued at $400,000, the low end of a $400,000–$600,000 range. The filing says the January 2024 Bausch agreement would result in reversal of that reserve because Bausch would not return the defective product.
- Other risks: Key risks include limited commercial adoption, manufacturing and third-party supplier dependence, regulatory and clinical uncertainty, pricing and reimbursement pressure, intellectual-property challenges, and the possibility of further financing needs. Eyenovia reported no material legal proceedings and no material cybersecurity incident in 2023.
Most important facts for investors to verify
- Confirm issuer identity: this filing is Eyenovia, Inc. (EYEN), despite the request metadata naming Hyperion DeFi, Inc.
- Review the audited financial statements and going-concern note, especially cash needs, available financing and the timing of expected cash depletion.
- Check subsequent filings for actual Mydcombi sales, gross margins, clobetasol launch timing and commercial uptake.
- Verify completion and terms of the Bausch rights transfer, including the cash/share payments, royalty obligation and clinical-supply reserve reversal.
- Track Avenue debt service, covenant compliance, maturity obligations and any additional equity or debt financing and resulting dilution.
- Monitor FDA discussions, Gen-2 device comparability, the MicroPine interim analysis, and whether management’s stated development milestones are achieved.